Soligenix (SNGX) Corporate Presentation summary

Company overview and strategy

• Focuses on developing and commercializing therapies for rare diseases with unmet medical needs, targeting both orphan diseases in oncology/inflammation and public health threats like ricin and viral diseases.

• Operates two segments: Specialized BioTherapeutics for orphan diseases and Public Health Solutions for vaccines/therapeutics for military and civilian use.

• Pipeline includes multiple fast track and orphan designated products, aiming for ~$2B in global annual sales.

Pipeline and clinical progress

• HyBryte (synthetic hypericin sodium) for cutaneous T-cell lymphoma (CTCL) showed positive Phase 3 results; a second confirmatory Phase 3 trial is enrolling, with FDA and EMA engagement ongoing.

• SGX302 for mild-to-moderate psoriasis demonstrated positive proof-of-concept and ongoing Phase 2a trial; targets a >$1B global market.

• SGX945 for Behçet's disease completed Phase 2a with biological efficacy and safety; estimated market >$200M.

• Public Health Solutions segment includes RiVax (ricin vaccine), SuVax/MarVax (filovirus vaccines), and CiVax (COVID-19 vaccine), all supported by significant NIH funding.

Market opportunity and commercialization

• HyBryte addresses a $250M global market for CTCL, with rapid response and favorable safety profile compared to existing therapies.

• SGX302 targets the large, underserved mild-to-moderate psoriasis market, with potential for both clinic and home use.

• SGX945 offers a new option for Behçet's disease, where current treatments are often ineffective or poorly tolerated.

• Public health vaccines have potential for government procurement and up to 3 Priority Review Vouchers, each valued at ~$100M.